Taipei, Taiwan
Taipei, Taiwan

Time filter

Source Type

Patent
Taiwan Liposome Company and TLC Biopharmaceuticals Inc. | Date: 2014-04-09

The invention provides a sustained release composition for intravitreal injection to the eye of a subject in need thereof. The sustained release composition contains an effective amount of a therapeutic agent in association with a nanosphere. The nanosphere contains a particle that comprises a particle-forming component capable of forming a vesicle, and an agent-carrying component capable of forming a complex with the therapeutic agent via electrostatic charge-charge interaction or hydrophobic-hydrophobic interaction. The particle-forming component has at least one head group moiety selected from a hydrophobic head group moiety, a polar head group moiety and a combination thereof. The agent-carrying component is a chemical entity that contains one or more negatively or positively charged groups.


Patent
Taiwan Liposome Co. and Tlc Biopharmaceuticals Inc. | Date: 2013-07-05

Disclosed herein are methods of treating arthritis, comprising administering a sustained release composition comprising liposomes comprising one or more phospholipids, cholesterol, and a therapeutic agent. The sustained release composition can be administered intraarticularly.


Patent
Taiwan Liposome Company and TLC Biopharmaceuticals Inc. | Date: 2012-11-02

The present invention provides a pharmaceutical composition comprising at least one hydrophobic camptothecin derivative or a pharmaceutically acceptable salt of said derivative and a polyethylene glycol (PEG) conjugated phospholipid. Also provided is a method to inhibit cancer cells in a subject in need thereof by administering the pharmaceutical composition of the present invention.


Patent
TLC Biopharmaceuticals Inc. and Taiwan Liposome Company | Date: 2014-03-07

The invention provides a sustained release composition for intravitreal injection to the eye of a subject in need thereof. The sustained release composition contains an effective amount of a therapeutic agent in association with a nanosphere. The nanosphere contains a particle that comprises a particle-forming component capable of forming a vesicle, and an agent-carrying component capable of forming a complex with the therapeutic agent via electrostatic charge-charge interaction or hydrophobic-hydrophobic interaction. The particle-forming component has at least one head group moiety selected from a hydrophobic head group moiety, a polar head group moiety and a combination thereof. The agent-carrying component is a chemical entity that contains one or more negatively or positively charged groups.


Patent
Taiwan Liposome Company and Tlc Biopharmaceuticals Inc. | Date: 2013-02-08

The present invention relates to pharmaceutical compositions comprising a combination of a lipid cake mixture comprising one or more phospholipids, with or without cholesterol, and a steroid solution comprising an ocular steroid, derivative thereof a pharmaceutically acceptable salt thereof or a prodrug thereof, wherein the total amount of the phospholipid in the said composition is about 0.1 umol to less than about 2.5 umol per 50 ul of pharmaceutical composition and the side effects of the ocular steroid are reduced. The pharmaceutical composition is preferably administered by ocular route to treat ophthalmic diseases.


Patent
Taiwan Liposome Company and Tlc Biopharmaceuticals Inc. | Date: 2014-03-15

The present invention relates to a pharmaceutical composition comprising at least one liposome, at least one polyvalent counterion donor or a pharmaceutically acceptable salt thereof, at least one monovalent counterion donor or a pharmaceutically acceptable salt thereof, and an amphipathic therapeutic agent. The present invention also relates to methods of inhibiting cancer cell growth, comprising administering the pharmaceutical composition described herein.


Patent
Taiwan Liposome Co. and TLC Biopharmaceuticals Inc. | Date: 2010-03-05

The present invention provides two new camptothecin derivatives, which were identified as S,R- and S,S-topotecan lactates, respectively. Both compounds have anticancer activities. Pharmaceutical compositions of the new camptothecin derivatives, and cancer therapies with the new camptothecin derivatives or their pharmaceutical compositions were also provided.


Patent
Taiwan Liposome Company and TLC Biopharmaceuticals Inc. | Date: 2013-11-12

The present invention is directed to a method of inhibiting cancer cell growth, comprising administering a pharmaceutical composition to a subject in need thereof. The pharmaceutical composition comprises at least one camptothecin derivative or a pharmaceutically acceptable salt thereof; and at least one PEG phospholipid, and provides a sustained release of topotecan as an active ingredient.


Patent
Taiwan Liposome Co. | Date: 2014-12-17

An ophthalmic drug delivery system that contains phospholipid and cholesterol for prolonging drug lifetime in the eyes.


Patent
TAIWAN LIPOSOME Co. and Tlc Biopharmaceuticals Inc. | Date: 2014-12-16

An ophthalmic drug delivery system that contains phospholipid and cholesterol for prolonging drug lifetime in the eyes.

Loading Taiwan Liposome Company collaborators
Loading Taiwan Liposome Company collaborators